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Background/aim: To determine the efficacy of lycopene, which is considered an antioxidant agent, in decreasing the cochlear damage
induced by cisplatin.
Materials and methods: A total of 38 rats were randomized into 4 groups: control, cisplatin, cisplatin + lycopene, and lycopene-treated
groups. In all groups, the distortion-product otoacoustic emission measurements were performed on days 0, 1, 2, and 5.
Results: There were no significant differences between the control and lycopene groups at any frequencies. In the cisplatin group, the
statistically significant differences were found in the measurements taken between day 0 and day 5 at all frequencies and between days 1
and 5 and days 2 and 5 at some frequencies (P < 0.05). In the cisplatin + lycopene group, a statistically significant difference was found
at some frequencies between the measurements taken on days 0 and 5, days 1 and 5, and days 2 and 5 (P < 0.05). Contrary to the results
found in the cisplatin group, hearing ability in the lycopene-treated group was observed as being preserved at low frequencies in the
measurements taken on days 0 and 5 and days 2 and 5.
Conclusion: The data of this study suggest that lycopene can prevent the development of ototoxicity induced by cisplatin, especially at
low frequencies. Studies on this issue with longer durations and different dose ranges may contribute to the identification of potentially
prophylactic effects of lycopene against cisplatin ototoxicity at higher frequencies, as well.
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1. Introduction
Ototoxicity is a widespread term for describing the
damage occurring on the cochlea and vestibular organs
by various therapeutic agents and/or chemicals. The
ototoxic effect of cisplatin is characterized by bilateral,
progressive, and irreversible sensorineural hearing loss.
Cisplatin demonstrates an ototoxic effect on outer hair cells
progressively from the base to the apex of cochlea. It causes
ototoxicity by consuming antioxidant enzymes. Many types
of protective agents have been used to decrease this damage,
and investigations into this issue are still continuing (1–6).
Lycopene is an antioxidant agent that is found in
tomatoes and tomato-based products (7). Lycopene has
a red pigment and belongs to the carotenoid family. It
protects cells from the damage induced by free radicals. In
addition, it strengthens intercellular bonds and accelerates
the development of cellular metabolism. The effectiveness
of fat-soluble lycopene increases in tissues and organs rich
in fat. Its antioxidant effect has been demonstrated in skin,

which is quite rich in fat content. It was also reported that
the oxidative damages resulting from diabetes mellitus
were ameliorated with the administration of lycopene (8). It
also has a cholesterol-decreasing effect. Lycopene provides
prophylaxis against some cancer types (breast, uterus,
liver, and prostate), Alzheimer disease, and cardiovascular
diseases and also slows down the aging process with its
antioxidant effects (9–11). The main dietary sources of
lycopene (at least 85%) are tomatoes and tomato products;
the remainder is obtained from apricot, pink grapefruit,
guava, watermelon, and papaya (12).
In this study, we aimed to determine the efficacy of
lycopene, which is considered to be an antioxidant agent,
in decreasing ototoxic damage induced by cisplatin.
2. Materials and methods
2.1. Study design
The present study was performed according to the approved
Industrial Animal Care and Use Committee guidelines
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(2012 / A - 08). A total of 38 Wistar albino rats weighing
between 150 and 200 g were used. During the study, the
animals were kept in automatically regulated chambers
under light and dark conditions, each lasting for 12 h a
day, at an ambient temperature of 22 ± 2 °C and 45%–50%
humidity. All rats were fed standard pellets, and every day
they were given fresh tap water. After anesthetizing the
animals with 50 mg/kg intramuscular (i.m.) ketamine and
5 mg/kg i.m. xylazine, they were brought into special silent
cabins for the application of subsequent procedures.
Otoacoustic emission measurements were used to
evaluate the hearing functions of all animals. In otoacoustic
emission measurements, distortion-product otoacoustic
emission test (DPOAE) values were used.
Rats were randomly divided into 4 groups. The control
group consisted of 7 rats, which received physiologic
saline at daily doses of 5 mL intraperitoneally (i.p.)
between days 0 and 5. The cisplatin group comprised 12
rats that received cisplatin i.p. at daily doses of 8 mg/kg
between days zero and 2. The cisplatin + lycopene group
included 12 rats that received cisplatin (8 mg/kg i.p. daily
between days 0 and 2) plus lycopene (5 mg/kg i.p. daily
between days 0 and 5). The lycopene group contained 7
rats, which received lycopene (5 mg/kg i.p. daily). In all
groups, DPOAE measurements were performed on days
0, 1, 2, and 5.
2.2. Otoacoustic emission measurements
The study included rats with normal DPOAE values. For
DPOAE test measurements, the GSI Audera DPOAE
(Grason Stadler, Madison, WI, USA) device was used. The
otoacoustic emission probe was placed into the external
auditory canal. For accuracy, the implantation and
calibration of the probe were examined using automated
measurement systems before each test. The measurements
were performed in a silent ambient environment with
sound pressure levels not exceeding 45 dB. Primary stimuli
levels were equalized at 65 dB for DPOAE measurements
(L1 = L2). Two separate frequencies (f1 and f2) were set
at a f2:f1 ratio equivalent to 1:22 to obtain the strongest
responses. DPOAE measurements were performed at
frequencies of 2003, 2519, 3175, 3996, 5039, 6351, 8003,
and 10,078 Hz, and the results were recorded.
2.3. Statistical analysis
Data were analyzed using SPSS 11.0 for Windows (SPSS
Inc., Chicago, IL, USA). The results for all items were
expressed as mean ± SEM, assessed within 95% reliance
and at a significance level of P < 0.05. Wilcoxon’s paired-t
test was used to analyze the data.
3. Results
Initially, the duration of the study was planned as 10 days.
The rats completed the first 5 days of the study without
any loss. However, on the sixth day, 9 rats died because of

enteritis, nephrotoxic effects, and weight loss possibly due
to cisplatin toxicity; consequently, the measurements were
terminated because of scarcity of experimental animals.
3.1. Control group
DPOAE measurements were performed on days 0, 1, 2,
and 5, and a statistically significant difference did not exist
at frequencies of 2003–10,078 Hz (P > 0.05) (Figure).
3.2. Cisplatin group
No statistically significant difference was found between
DPOAE measurements performed on days 0 and 1, days
0 and 2, or days 1 and 2. However, statistically significant
differences were found between measurements taken on
days 0 and 5 at all frequencies; between days 1 and 5 in
measurements performed at the frequencies of 3175, 3996,
5039, 6351, 8003, and 10,078 Hz; and between days 2 and
5 in measurements performed at the frequencies of 2003,
3175, 3996, 5039, 6351, 8003, and 10,078 Hz (P < 0.05)
(Figure).
3.3. Cisplatin + lycopene group
In DPOAE measurements, no statistically significant
difference was found between the measurements of days 0
and 1, days 0 and 2, or days 1 and 2. Statistically significant
differences were found between the measurements
performed on days 0 and 5 at the frequencies of 3175,
3996, 5039, 6351, 8003, and 10,078 Hz; between the
measurements of days 1 and 5 at frequencies of 3175,
3996, 5039, 6351, 8003, and 10,078 Hz; and between the
measurements taken on days 2 and 5 at frequencies of
3996, 5039, 6351, 8003, and 10,078 Hz (P < 0.05). Contrary
to the cisplatin group, in the cisplatin + lycopene group,
the hearing ability was observed as being preserved in
the measurements of days 0 and 5 at frequencies of 2003
Hz and 2519 Hz and the measurements of days 2 and 5 at
frequencies of 2003 Hz and 3175 Hz (Figure).
3.4. Lycopene group
DPOAE measurements were performed on days 0, 1, 2,
and 5, and a statistically significant difference did not exist
at frequencies of 2003–10,078 Hz (P > 0.05) (Figure).
4. Discussion
Cisplatin is an antineoplastic drug that is frequently used
in head, neck, testicular, and ovarian malignancies. Many
investigations have been performed to ensure the safe usage
of this chemotherapeutic agent due to its important adverse
effects, such as ototoxicity. For instance, in studies performed
by Teranishi and Nakashima and by Kalkanis et al., reductions
were observed in hearing loss and cochlear damage by using
systemic vitamin E administration (1,13). In similar studies,
the potentially prophylactic effects of different antioxidant
agents, e.g., erdosteine, aminoguanidine, and caffeic acid,
were demonstrated (3–5).
The antioxidant effect of the carotenoid family is a result
of their extended tetraterpene chemical configuration,
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Figure. Variations in amplitudes of distortion products
otoacoustic emissions with frequency for different time points in
the study groups.

in which a total of 40 carbon units are bound end-toend with single and double conjugated bonds. The free
radical-neutralizing property of this chemical formation,
with its protective effects against some cancer types,
cardiac dysfunctions, and degenerative eye diseases, has
been revealed in many investigations. As a result of these
studies, the prominent antioxidant effect of lycopene is
associated with preventing ROS damage via free radical
scavenging and detoxifying lipid peroxides (14–16).
Studies performed with lycopene from the carotenoid
family have demonstrated that lycopene induces decreased
levels of malondialdehyde, which is the end product of

fatty acid oxidation and is known to correlate with the
degree of oxidative damage. However, as shown in various
studies, lycopene also increases activities of endogenous
antioxidants such as superoxide dismutase and glutathione
peroxidase (14,17,18).
In a previous study, the antioxidant effects of synthetic
and naturally occurring (i.e. found in tomatoes) forms
of lycopene were compared with placebo-group patients.
Decreased lipid peroxidation and oxidative stress were
found in both lycopene-supplementing groups when
compared with the placebo-group patients. In comparative
analysis, a statistically significant difference was noted
between the lycopene groups. As a result, it was suggested
that dietary intake of natural lycopene is favorable against
oxidative stress; however, the synthetic form is more
bioavailable and more effective (19).
The protective effect of lycopene against chemotherapy
agent toxicities such as cisplatin-induced nephrotoxicity,
doxorubicin-induced myocardial or kidney toxicity,
gentamycin-induced nephrotoxicity, and oxidative stress
was shown in animal studies (20–22).
In the present study, we evaluated the protective effect
of this potent antioxidant agent against ototoxicity induced
by cisplatin. However, the study was terminated earlier
than planned due to the loss of the majority of the rats
on the sixth day, from the systemic toxicity of cisplatin.
The results of the DPOAE measurements performed in
cisplatin-administered rats revealed statistically significant
deteriorations at all frequencies, while hearing ability was
preserved at low frequencies in the cisplatin + lycopeneadministered group. These data suggest that lycopene
can prevent the development of ototoxicity, especially at
lower frequencies. Future studies on this issue with longer
durations and different dose ranges may contribute to
the identification of potentially prophylactic effects of
lycopene against cisplatin ototoxicity at low and higher
frequencies, as well.
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